NSAIDs and gastrointestinal cancer prevention

Drugs

Volumn 62, Issue 6, 2002, Pages 945-956

  Jolly, Kate ^a   Cheng, Kar K ^a   Langman, Michael J S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; ESOPHAGUS CANCER; GALLBLADDER CANCER; HUMAN; LIVER CANCER; PANCREAS CANCER; REVIEW; STOMACH CANCER;

EID: 0036236841     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262060-00006     Document Type: Review

References (57)

1. Randomised comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps
2. Flat adenomas
3. Do NSAIDs prevent colorectal cancer?
4. Excess risk of lymphoma, leukemia and myeloma in patients with rheumatoid arthritis
5. Incidence of cancer among patients with rheumatoid arthritis
6. Aspirin use and chronic diseases: A cohort study of the elderly
7. Aspirin use and incidence of large bowel cancer in a California retirement
8. Aspirin and colorectal cancer: The Leisure World Cohort revisited
9. Aspirin use and risk of fatal cancer
10. Aspirin use and lung, colon and breast cancer incidence in a prospective study
11. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
12. Aspirin and the risk of colorectal cancer in women
13. Low incidence of colorectal cancer in patients with rheumatoid arthritis
14. Rheumatoid arthritis and the risk of malignancy
15. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer
16. Relative risk of malignant tumors in analgesic abusers: Effects of long-term intake of aspirin
17. Colorectal cancer risk, chronic illnesses, operations, and medications: Case-control results from the Melbourne Colorectal Cancer study
18. A hypothesis: Non-steroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer
19. Aspirin use, cancer, and polyps of the large bowel
20. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer
21. Non-steroidal anti-inflammatory drugs and colorectal cancer
22. Diseases preceding colon cancer: A case-control study among veterans
23. Non-steroidal anti-inflammatory drug use and protection against colorectal cancer in women
24. Risk factors of colorectal cancer in inflammatory bowel disease
25. Long-term use of non-steroidal anti-inflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia
26. Aspirin and colorectal cancer
27. Nonsteroidal anti-inflammatory drug use and reduced risk of large bowel cancel
28. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: Effects of dosage and timing
29. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
30. Reduced risk of colorectal cancer among long-term users of aspirin and non-aspirin non-steroidal antiinflammatory drugs
31. Low dose aspirin and incidence of colorectal tumors in randomised trial
32. Aspirin use and colorectal cancer: Post-trial follow-up data from the Physicians' health study
33. Aspirin and reduced risk of esophageal carcinoma
34. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer
35. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel
36. Aspirin protects against gastric cancer: Results of a case-control study from Moscow, Russia
37. Aspirin and risk for gastric cancer: A population-based case-control study in Sweden
38. Life-style factors and medical conditions in relation to esophageal cancer by histologic type in a low-risk population
39. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal ademonas: Case-control study of subjects participating in the Nottingham faecal occult blood screening programme
40. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals
41. Size-dependent increase in prosanoid levels in adenomas of patients with familial adenomatous polyposis
42. Antitumor activity of indomethacin on methyloxymethanol-induced large bowel tumors in rats
43. Sulindac suppresses tumorigenesis in the Min mouse
44. Cyclooxygenase-2 over-expression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis
45. Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam
46. Non-steroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions
47. Antineoplastic drugs sulindac sulphide and sulphone inhibit cell growth by inducing apoptosis
48. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction
49. Aspirin induction of apoptosis in esophageal cancer: A potential for chemoprevention
50. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
51. Barrett's oesophagus, oesophageal cancer and colon cancer; an explanation of the association and cancer chemopreventive potential of non-steroidal anti-inflammatory drugs
52. Induction of apoptosis by cyclo-oxygenase-2 inhibitor NS398 through a cytochrome-c dependent pathway in esophageal cancer cells
53. Sulindac causes regression of rectal polyps in familial adenosis polyposis
54. Treatment of colonic and rectal adenomas with sulindac in familial adenosis polyposis